Sol-Gel Technologies SLGL
NASDAQ SLGL
$70.14 +0.04 (+0.06%)
As of: Sep 4, 2026 · 3:09 PM EDT

Sol-Gel Technologies (SLGL) Interest Expenses (2018 - 2026)

Sol-Gel Technologies (SLGL) posted quarterly Interest Expenses of $58.5 million for Q4 2025, up 17.5% year-over-year from $49.8 million in Q4 2024, and up 15418.3% quarter-over-quarter from $377000.0 in Q2 2025.

Analysis

Sol-Gel Technologies (SLGL) Interest Expenses (2018 - 2026) Analysis & Trends

Sol-Gel Technologies (SLGL) has reported Interest Expenses for 10 consecutive years, with $58.5 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Interest Expenses rose 17.5% year-over-year to $58.5 million; the TTM figure through Mar 2026 stood at $377000.0 (up 18.18% YoY), while the FY2025 annual figure was $58.5 million, up 17.5% from the prior year.
  • Interest Expenses improved to $58.5 million in Q4 2025 per SLGL's latest filing, from $377000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $58.5 million in Q4 2025 and bottomed at $319000.0 in Q2 2024.
  • Historically, Interest Expenses has averaged $28.9 million across 5 years, with a median of $44.7 million in 2022.
  • Annual changes were most pronounced in 2022 — Interest Expenses soared 10854.41% — and 2024, when it gained 3.92%.
  • Sol-Gel Technologies' Interest Expenses stood at $408000.0 in 2021, then jumped by 10854.41% to $44.7 million in 2022, then climbed by 7.2% to $47.9 million in 2023, then advanced by 3.92% to $49.8 million in 2024, then gained by 17.5% to $58.5 million in 2025.
  • Business Quant data shows SLGL's Interest Expenses at $58.5 million in Q4 2025, $377000.0 in Q2 2025, and $49.8 million in Q4 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Expense (Qtr)
1 Vertex Pharmaceuticals 138.51 Bn 130.66 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.24 Bn 77.25 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.46 Bn 58.28 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.89 Bn 52.75 Bn 52.00 Mn -
5 Revolution Medicines 44.02 Bn 44.02 Bn - 23.78 Mn
6 BeOne Medicines 39.95 Bn 34.85 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.49 Bn 32.19 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.43 Bn 27.59 Bn - 93.62 Mn
9 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 20.27 Mn
10 Sol-Gel Technologies 195.40 Mn 147.47 Mn - 481,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 481,000.00
Jun 30, 2025 380,000.00
Jun 30, 2024 352,000.00
Jun 30, 2023 557,000.00
Jun 30, 2022 329,000.00
Jun 30, 2021 9,000.00
Jun 30, 2020 481,000.00
Jun 30, 2019 359,000.00
Jun 30, 2018 379,000.00